![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00215462 |
The purpose of this study is to collect anti-tumor activity of vinorelbine when given to patients with esophageal or gastric tumors. We will also collect information on the toxicities of vinorelbine in these patients.
Condition | Intervention | Phase |
Esophageal Cancer Gastric Cancer Stomach Cancer |
Drug: Vinorelbine |
Phase II |
MedlinePlus related topics: | Cancer Esophageal Cancer Esophagus Disorders Stomach Cancer |
Drug Information available for: | Vinorelbine Vinorelbine tartrate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma |
Estimated Enrollment: | 32 |
Study Start Date: | June 2000 |
Study Completion Date: | August 2005 |
Primary Completion Date: | August 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Massachusetts General Hospital |
Beth Israel Deaconess Medical Center |
Principal Investigator: | Matthew Kulke, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Matthew Kulke, MD ) |
Study ID Numbers: | 00-012 |
First Received: | September 14, 2005 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00215462 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
![]() |